RC110 could have been used outside of AML, but the protection would only have been around the use of bisantrene (i.e. patent protection for cardioprotection), or orphan drug designation. This is not worthless, but it is obviously not as good as patent protection on the drug formulation.
This was all explained at the time and was one of the major reasons we concentrated on orphan diseases like AML, kidney cancer and melanoma where we could obtain orphan drug designation and protection.
I should add that RC220 has been in development since early 2020 - it was one of the first things I started working on when I became Race’s CSO as I knew we needed RC220 if we were going to get the most out of bisantrene commercially.
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-16
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
-0.055(3.61%) |
Mkt cap ! $250.5M | |||
| Open | High | Low | Value | Volume |
| $1.53 | $1.58 | $1.47 | $114.6K | 76.33K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 2470 | 1 |
View Market Depth
| Last trade - 14.16pm 12/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |